Effect of administration of corticotropin-releasing hormone and glucocorticoid on arginine vasopressin response to osmotic stimulus in normal subjects and patients with hypocorticotropinism without overt diabetes insipidus.
We examined the effect of CRH administration on the response of plasma arginine vasopressin (AVP) induced by an osmotic stimulus in six normal subjects and five patients with hypocorticotropinism without overt diabetes insipidus (four patients with Sheehan's syndrome and one with idiopathic pituitary dwarfism with ACTH deficiency). Hypertonic saline infusion (855 mmol/L saline solutions at a rate of 205 mumol/kg.min for 10 min) increased plasma AVP 5.7-fold (P less than 0.01) in normal subjects and 2.4-fold (P less than 0.05) in the patients. CRH administration significantly augmented the plasma AVP response to the osmotic stimulus in the normal subjects, but not in the patients with hypocorticotropinism. CRH administration alone did not influence plasma AVP. These findings suggest that a central CRH-related mechanism(s) was at least partly involved in the augmentation of AVP release. Based on the relatively low plasma AVP response to the osmotic stimulus in patients and their lower plasma AVP levels and higher plasma osmolality under basal conditions, we suggest that patients with hypocorticotropinism have partial diabetes insipidus, in which impairment of central CRH action might be, at least in part, involved. The response of plasma AVP to the osmotic stimulus was attenuated significantly when the patients were given cortisol. Since basal PRA, plasma aldosterone, plasma osmolality, hematocrit, body weight, mean blood pressure, and heart rate were similar with and without cortisol administration, this effect of cortisol may have been due to central suppression of the AVP response to the osmotic stimulus.
Yamada
K
K
Second Department of Internal Medicine, Chiba University School of Medicine, Japan.
Tamura
Y
Y
Yoshida
S
S
D000293:Adolescent; D000309:Adrenal Insufficiency / Q000097:blood*; D000324:Adrenocorticotropic Hormone / Q000172:deficiency; D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D001127:Arginine Vasopressin / Q000097:blood*; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D003919:Diabetes Insipidus / Q000097:blood*; D004393:Dwarfism, Pituitary / Q000097:blood; D005938:Glucocorticoids / Q000494:pharmacology*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000097:blood; D007018:Hypopituitarism / Q000097:blood; D008297:Male; D011388:Prolactin / Q000097:blood; D011933:Reagent Kits, Diagnostic; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage; D001615:beta-Endorphin / Q000097:blood
D005938:Glucocorticoids; D011933:Reagent Kits, Diagnostic; D012462:Saline Solution, Hypertonic; D001127:Arginine Vasopressin; D000450:Aldosterone; D001615:beta-Endorphin; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013006:Growth Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone